PCA(P)(2021)09 - Dispensing Pool
Published: 08/06/21
The Scottish Government have released circular PCA(P)(2021)09 which advises of changes to the Drug Tariff with respect to remuneration arrangements to regulate the delivery of the remuneration Global Sum for 2020/21.
Detail - NHS Pharmacy First Scotland
An additional £0.600m will be allocated to the NHS Pharmacy First Scotland activity pot for the quarter January to March 2021. This will be apportioned as £0.200m for each month (January to March) with the maximum activity fee uncapped for the period.
Smoking Cessation
An additional £0.641m will be proportionally allocated to the Smoking Cessation activity pot for the quarter January to March 2021 for distribution. This will be attributed proportionally to all activity across the year on smoking cessation.
Emergency Hormonal Contraception
An additional £0.582m will be proportionally allocated to the EHC service pot for the quarter January to March 2021 for distribution. This will be attributed proportionally to all activity across the year on EHC.
Fixed Payment
A fixed sum payment of £1,000 will be paid to each contractor on the Boards Pharmaceutical List on the 1st day of March 2021. The payment is in recognition of the additional adjustments made to pharmacy premises during the pandemic. This will appear as ‘C19 Premises’ on your payment schedule.
Dispensing Pool
An adjusted Dispensing Pool payment is to be introduced for the dispensing month of March 2021 only. The payment to each eligible contractor will be calculated as a percentage of the available additional pool of £2,413,922 of the base dispensing pool payment – or where it applies the minimum monthly payment. This will be paid as ‘DP_Balance’ adjustment
Consultation
Community Pharmacy Scotland has been consulted on the Drug Tariff amendments and the contents of this circular.
Action
NHS Boards are asked to:
note the contents of this circular;
copy this circular to all community pharmacy contractors on their pharmaceutical lists, Health and Social Care Partnerships and the Area Pharmaceutical Board.
